Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced the appointment of Paul Eng, Ph.D., as Senior Vice President, Drug Development. Dr. Eng will lead all clinical development operations for Synergy’s pivotal phase 3 program with plecanatide in patients with irritable bowel syndrome with constipation (IBS-C).
Paul Eng, Ph.D., Senior V.P. Drug Development, Synergy Pharmaceuticals Inc. (Photo: Business Wire)
“Dr. Paul Eng brings a considerable amount of recent experience and valuable expertise, having successfully led late-stage clinical programs through NDA and drug approval for chronic idiopathic constipation (CIC) and IBS-C,” said Gary S. Jacob, Ph.D., Chairman and CEO of Synergy Pharmaceuticals. “We are fortunate to have Paul join us and look forward to his contributions as we quickly advance plecanatide into phase 3 registration trials for IBS-C and prepare for a CIC NDA filing next year.”
“I am excited to be joining Synergy at such a critical stage of development,” said Dr. Eng. “Plecanatide has already demonstrated excellent clinical potential for treating IBS-C and CIC patients in phase 2 trials and I look forward to further establishing plecanatide’s efficacy and safety profile in pivotal phase 3 trials.”
Prior to joining Synergy, Dr. Eng was Director of Gastroenterology Clinical Development at Forest Laboratories, Inc., where he was chiefly responsible as study director for the successful pivotal phase 3 clinical trials that led to NDA and drug approval for treatment of CIC and IBS-C. Dr. Eng has a considerable record of achievement in clinical development and medical affairs, with positions at American Home Products (Wyeth) and Life Medical Sciences prior to joining Forest Laboratories in 2001. Dr. Eng holds a Ph.D., Immunology, M.S., Human Genetics and B.S., Physiology from Rutgers University.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts